%0 Journal Article
%A Leichsenring, Jonas
%A Volckmar, Anna-Lena
%A Magios, Nikolaus
%A Morais de Oliveira, Cristiano Manuel
%A Penzel, Roland
%A Brandt, Regine
%A Kirchner, Martina
%A Bozorgmehr, Farastuk
%A Thomas, Michael
%A Schirmacher, Peter
%A Warth, Arne
%A Endris, Volker
%A Stenzinger, Albrecht
%T Synonymous EGFR variant p.Q787Q is neither prognostic nor predictive in patients with lung adenocarcinoma.
%J Genes, chromosomes & cancer
%V 56
%N 3
%@ 1045-2257
%C New York, NY
%I Wiley-Liss
%M DKFZ-2017-00900
%P 214 - 220
%D 2017
%X Patients with non-small cell lung cancer (NSCLC) harboring activating mutations in the Epidermal Growth Factor Receptor (EGFR) benefit from targeted therapies. A synonymous polymorphism (rs1050171, p.Q787Q) was shown to be associated with improved overall survival (OS) in colorectal cancer patients. As data in NSCLC are limited, we retrospectively analyzed associations of p.Q787Q with clinicopathological parameters including clinical response and outcome in patients with lung adenocarcinoma (ADC) who received tyrosine kinase inhibitor (TKI) therapy. Of 642 ADC patients whose tumors were profiled by next generation sequencing, 102 (15.9
%F PUB:(DE-HGF)16
%9 Journal Article
%$ pmid:27750395
%R 10.1002/gcc.22427
%U https://inrepo02.dkfz.de/record/120471